Clinical Trial Update: NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study [Phase 2]

View source ↗

Summary

Phase 2 exploratory trial evaluating NALIRIFOX in combination with camrelizumab for borderline resectable pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• NALIRIFOX (liposomal irinotecan + 5-fluorouracil/leucovorin)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Borderline Resectable Pancreatic Cancer | Phase 2 | Status: UNKNOWN